Bapineuzumab
Bapineuzumab
Bapineuzumab (pronunciation: ba-pin-ew-zu-mab) is a monoclonal antibody that was under development as a potential treatment for Alzheimer's disease.
Etymology
The name "Bapineuzumab" is derived from the combination of the words "Bap" and "ineuzumab". "Bap" is an abbreviation for "beta-amyloid precursor", referring to the protein that is targeted by the drug. "Ineuzumab" is a common suffix used in the names of monoclonal antibodies.
Mechanism of Action
Bapineuzumab works by targeting and clearing beta-amyloid plaques from the brain. Beta-amyloid plaques are a hallmark of Alzheimer's disease, and are believed to contribute to the neurodegeneration seen in this condition.
Clinical Trials
Several clinical trials were conducted to assess the efficacy and safety of Bapineuzumab. However, the development of the drug was discontinued after it failed to show significant benefits in improving cognitive function in Alzheimer's patients.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Beta-amyloid: A protein that is the main component of the amyloid plaques found in the brains of Alzheimer patients.
- Alzheimer's disease: A progressive disease that destroys memory and other important mental functions.
External links
- Medical encyclopedia article on Bapineuzumab
- Wikipedia's article - Bapineuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski